Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Abstract: The present disclosure provides a use of an osmolyte in the manufacture of a medicament treating protein aggregation related disorders, specifically provides a use of an osmolyte in the manufacture of a medicament treating TGFBI corneal dystrophies. The osmolyte is selected from a group consisting of betaine, raffmose, sarcosine, taurine and/or any pharmaceutically acceptable derivatives thereof.

Abstract: This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal endothelial cells from a mixture of cell.

Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Abstract: This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal en dothelial cells from a mixture of cell.

Abstract: An OCT image of an eye which has been subject to a DSAEK corneal transplant, in which a Descement's membrane in the cornea has been replaced by a graft, is processed to identify the outline of the graft. The process includes the steps of: computationally extracting the boundary of the cornea including the graft; computationally detecting the corners of the graft; computationally extracting points on the boundary between the graft and the original cornea; and computationally fitting the points on the boundary between the graft and the original cornea smoothly into a curve. The outline of the graft is then displayed. A graft profile may be generated, indicating the thickness of the graft at each point along its length.

Abstract: An OCT image of an eye which has been subject to a DSAEK corneal transplant, in which a Descement's membrane in the cornea has been replaced by a graft, is processed to identify the outline of the graft. The process includes the steps of: computationally extracting the boundary of the cornea including the graft; computationally detecting the corners of the graft; computationally extracting points on the boundary between the graft and the original cornea; and computationally fitting the points on the boundary between the graft and the original cornea smoothly into a curve. The outline of the graft is then displayed. A graft profile may be generated, indicating the thickness of the graft at each point along its length.